Protocol Ledger

NCT07246863 · Phase II · RECRUITING

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

Interventional Phase II clinical trial protocol NCT07246863 sponsored by CatalYm in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-10-07 Enrollment: 131 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07246863
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)131 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07246863
Protocol FieldVerified Registry Value
NCT IdentifierNCT07246863
Consolidated Lead SponsorCatalYm
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment131 participants (ESTIMATED)
Registered Start Date2025-10-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07246863
Hospital Research SiteLocationSite Profile
USC Norris Comprehensive Cancer Center and Keck MedicineLos Angeles, CAOpen Hospital Dossier ->
NYU Langone Hospital - Long IslandMineola, NYOpen Hospital Dossier ->
Duke University Medical CenterDurham, NCOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI